News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Northwest Biotherapeutics gives brain cancer trial update


Posted on: 05/25/2006

Northwest Biotherapeutics gives brain cancer trial update

24th May 2006
By Helen Marshall

Northwest Biotherapeutics has released encouraging updated phase I survival and progression data on patients who have received DCVax-Brain, a therapeutic personalized cancer vaccine.

The phase I clinical trial of DCVax-Brain involved patients with Glioblastoma multiforme (GBM), the deadliest form of brain cancer. Dendritic cell-based immunotherapy, such as that used in the DCVax-Brain vaccine, uses autologous dendritic cells that are pulsed with tumor antigens. This therapeutic approach aims at safely stimulating anti-tumor immune responses to prevent tumor recurrence or progression.

Observed findings include that six of 10 patients are still alive, with median survival of over 22.1 months (and continuing), and that five of 10 patients continue to show no signs of cancer recurrence, with median follow-up time of 34.8 months.

Results to date also demonstrate that survival time ranges from 13.5 to 41.9 months (and continuing) and median time to progression (i.e. tumor recurrence) is over 14.9 months (and continuing).

Without such treatment, GBM has historical median times to progression and death of approximately eight and 15 months, respectively.

 

Print Article Email A Fiend Your Opinion

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740